Cambridge Cognition Reports Stable Share Option Pool in Latest Block Listing Return

Cambridge Cognition Holdings ( (GB:COG) ) has provided an announcement.

Cambridge Cognition Holdings, a neuroscience technology group, develops digital cognitive assessment tools that are delivered via touchscreen and voice interfaces under the CANTAB and Winterlight brands. Its CANTAB Pathway suite offers scalable solutions ranging from brief cognitive screening to disease-specific modules for conditions such as Parkinson’s, ADHD, multiple sclerosis and Alzheimer’s, aimed at both consumer and professional healthcare markets.

The company has filed a block listing return for its share option scheme, confirming that no new securities were issued or allotted during the period from 1 October 2025 to 31 March 2026. As a result, the balance of unallotted ordinary shares under the scheme remains unchanged at 466,316, signalling stability in its equity-based incentive arrangements and no recent dilution for existing shareholders over the reporting period.

The most recent analyst rating on (GB:COG) stock is a Hold with a £36.00 price target. To see the full list of analyst forecasts on Cambridge Cognition Holdings stock, see the GB:COG Stock Forecast page.

Spark’s Take on COG Stock

According to Spark, TipRanks’ AI Analyst, COG is a Neutral.

Overall score reflects weak financial performance driven by declining revenue, ongoing losses, and negative operating/free cash flow, partially offset by improved equity on the balance sheet. Technicals are mixed (short-term strength but longer-term downtrend and overbought RSI), while valuation is constrained by loss-making results and no stated dividend yield.

To see Spark’s full report on COG stock, click here.

More about Cambridge Cognition Holdings

Cambridge Cognition Holdings is a neuroscience technology company specialising in digital cognitive assessments that support scientific discovery, accelerate drug development and improve patient care. Its touchscreen and voice-based tools, delivered under the CANTAB, Winterlight and CANTAB Pathway brands, target both consumer home-use and clinical or research settings, including disease-specific modules for neurological and psychiatric conditions.

The CANTAB Pathway product suite includes CANTAB One for brief overall cognitive checks, CANTAB Insight for deeper analysis across multiple cognitive domains and CANTAB Plus for specialist, indication-focused assessments. These solutions are designed to minimise specialist administration, reduce administrator bias and provide objective, near real-time results that support longitudinal monitoring of cognitive function in diverse healthcare and research environments.

Average Trading Volume: 32,284

Technical Sentiment Signal: Hold

Current Market Cap: £17.23M

See more insights into COG stock on TipRanks’ Stock Analysis page.